Alexion Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alexion Pharmaceuticals Inc.
The company announced a $336m series C round, six months after it raised an $80m series B, to support development of an easily administered treatment ADG20.
Abbott’s’s distribution of its BinaxNOW COVID-19 Ag Self Test to US retailers increases to three the number of OTC tests for the virus that CVS offers, along with Ellume’s and Labcorp’s test kits also available under EUAs granted by FDA.
GlaxoSmithKline's market value has slipped in the past three years and the number of failures in the clinic have grown. The major's leadership will be casting nervous glances towards a major shareholder that has a reputation for aggressive restructuring calls.
Russia’s Pharmapark has added Prestige BioPharma’s HD204 biosimilar bevacizumab product to the firms’ commercialization partnership, two years after kicking off the partnership with trastuzumab.
- Large Molecule
- Other Names / Subsidiaries
- Alexion Pharma K.K. (formerly Legend K.K. or Legend Pharma Co., Ltd.) (Japan)
- Enobia Pharma Corp.
- Portola Pharmaceuticals, Inc. (PTLA)
- Synageva BioPharma Corp.
- Syntimmune, Inc.
- Taligen Therapeutics, Inc.
- Wilson Therapeutics AB